Document text
Principal Investigator: Erica Ollmann Saphire
Organization: LA JOLLA INSTITUTE FOR IMMUNOLOGY
Fiscal Year: 2021
Award: $1,903,653
Funding agency: National Institute of Allergy and Infectious Diseases
Abstract
SARS-CoV-2 rapidly emerged and spread throughout the globe to infect millions of people. The SARS-CoV-2
spike protein is the primary target of the immune response and thus most vaccine development efforts used
the spike protein as an immunogen to elicit protective antibodies. However, as SARS-CoV-2 infections surged
in multiple waves, viruses bearing mutations in spike protein emerged, which rendered vaccines that were
developed based on initial sequences of the spike protein less effective. The persistence of these variants and
the likely inevitable development of new variants requires continued efforts to develop novel immunogens
based on SARS-CoV-2 spike that can elicit durable protection that remains effective in the face of new
mutations. The Coronavirus Immunotherapeutics Consortium (CoVIC) has gathered hundreds of monoclonal
antibodies from researchers around the world and is undertaking a broad, deep and multidisciplinary analysis
of the binding sites of these antibodies to understand which epitopes on spike are associated with
protection. We will examine at an atomic level the binding footprint of protective antibodies and assess
whether certain epitopes are more resistant to the effects of spike mutations. We will also test a novel mouse
model of SARS-CoV-2 infection that involves mice with triple knockin of human ACE2, TMPRSS2, and FcRN.
These mice may better recapitulate the mechanism of infection and pharmacokinetics of protective antibodies
elicited in response to vaccination. We will use these mice to examine the protective capacity of antibodies in
longitudinal samples from individuals who received currently available vaccines. Given the critical role of data
sharing and dissemination for rapid responses to emerging mutations and to maximize use of the information
generated in this proposal by the broader scientific community, we are building the CoVIC database, termed
CoVIC-DB, which allows real-time dissemination and analysis of information on this array of protective
antibodies. CoVIC-DB is an open, web-accessible database that will serve as a long-term resource to
understand key properties of antibodies against SARS-CoV-2 spike protein.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><ACE2><Adopted><Animal Model><Animal Models and Related Studies><Antibodies><Antibody Binding Sites><Antibody Response><Antigenic Determinants><Antigens><Assay><Binding><Binding Determinants><Binding Proteins><Bioassay><Biologic Assays><Biological Assay><Blood Plasma><COVID-19><COVID-19 S protein><COVID-19 antibody><COVID-19 infection><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID19><COVID19 S protein><COVID19 infection><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><CV-19><CV19><Cellular Assay><Clinical Treatment Moab><CoV-2><CoV2><Comment><Commentary><Communities><Complex><Coronaviridae><Coronavirus><Data><Data Bases><Databases><Development><Disease><Disorder><Drug Kinetics><ELISA><Editorial Comment><Enzyme-Linked Immunosorbent Assay><Epitheliasin Gene><Epitopes><FcRn><FcRn neonatal transfer protein><Feedback><Fostering><Genetic Alteration><Genetic Change><Genetic defect><Goals><Human><Immune Targeting><Immune response><Immunization><Immunologic Sensitization><Immunologic Stimulation><Immunological Sensitization><Immunological Stimulation><Immunological response><Immunostimulation><Immunotherapeutic agent><Individual><Infection><Investigators><Knock-in><Lead><Length><Ligand Binding Protein><Ligand Binding Protein Gene><Link><Measures><Mice><Mice Mammals><Modern Man><Molecular Interaction><Monoclonal Antibodies><Murine><Mus><Mutation><Mutation Analysis><PBMC><PRSS10><Paratopes><Pathogenesis><Pb element><Peripheral Blood Mononuclear Cell><Pharmacokinetics><Plasma><Plasma Serum><Position><Positioning Attribute><Property><Protein Binding><Proteins><Published Comment><Research Personnel><Research Resources><Researchers><Resistance><Resources><Reticuloendothelial System, Serum, Plasma><Role><SARS corona virus 2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 antibody><SARS-CoV-2 infection><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 antibody><SARS-CoV2 infection><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Site><Standardization><Structure><TMPRSS2><TMPRSS2 gene><Testing><Therapeutic antibodies><Time><Vaccinated><Vaccination><Vaccine Design><Vaccines><Variant><Variation><Viewpoint><Viral><Virus><Wuhan coronavirus><access to vaccination><access to vaccines><angiotensin converting enzyme 2><angiotensin converting enzyme II><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody combining site><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><base><bound protein><cell assay><community building><corona virus><corona virus disease 2019><corona virus disease 2019 vaccine><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 antibody><coronavirus disease 2019 infection><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><data base><data dissemination><data sharing><design><designing><develop a vaccine><development of a vaccine><developmental><genome mutation><hCoV19><heavy metal Pb><heavy metal lead><host response><immune drugs><immune system response><immune-based therapeutics><immunogen><immunologic preparation><immunologic therapeutics><immunoresponse><immunotherapeutics><immunotherapy agent><in vivo><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><knockin><mAbs><member><model of animal><model organism><mouse model><multidisciplinary><murine model><nCoV2><neonatal Fc receptor><new vaccines><next generation vaccines><novel><novel vaccines><resistance mutation><resistant><resistant mutation><response><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><social role><therapeutic candidate><tool><vaccination access><vaccination availability><vaccine access><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine antibodies><vaccine availability><vaccine development><vaccine efficacy><vaccine for novel coronavirus><vaccine formulation><vaccine induced antibodies><vaccine-induced antibodies><variants of concern><web-accessible>